share_log

Health Canada Has Issued A Notice Of Compliance For Sanofi/Regeneron Dupixent (Dupilumab Injection) For The Treatment Of Patients Aged 1 Year And Older, Weighing At Least 15 Kg, With Eosinophilic Esophagitis

Benzinga ·  Sep 12 19:38

This approval expands the initial Health Canada Notice of Compliance for eosinophilic esophagitis in May 2023 for patients aged 12 years and older, weighing at least 40 kg.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment